Literature DB >> 26390245

A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.

Tamar Krishnamurti1, Steven Woloshin2, Lisa M Schwartz2, Baruch Fischhoff3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26390245     DOI： 10.1001/jamainternmed.2015.5355

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  10 in total

Review 1.  Evaluation of technologies approved for supplemental payments in the United States.

Authors:  Timothy J Judson; Sanket S Dhruva; Rita F Redberg
Journal:  BMJ       Date:  2019-06-17

2.  Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Authors:  Huseyin Naci; Olivier J Wouters; Radhika Gupta; John P A Ioannidis
Journal:  Milbank Q       Date:  2017-06       Impact factor: 4.911

3.  The Role of Disease Label in Patient Perceptions and Treatment Decisions in the Setting of Low-Risk Malignant Neoplasms.

Authors:  Peter R Dixon; George Tomlinson; Jesse David Pasternak; Ozgur Mete; Chaim M Bell; Anna M Sawka; David P Goldstein; David R Urbach
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

4.  The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.

Authors:  Thomas J Hwang; Jonathan J Darrow; Aaron S Kesselheim
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

5.  Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.

Authors:  Sanket S Dhruva; Jonathan J Darrow; Aaron S Kesselheim; Rita F Redberg
Journal:  J Gen Intern Med       Date:  2022-02-09       Impact factor: 5.128

6.  "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication.

Authors:  Ilona Fridman; Peter A Ubel; Jennifer Blumenthal-Barby; Cameron V England; Judith S Currier; Nir Eyal; Kenneth A Freedberg; Scott D Halpern; Colleen F Kelley; Daniel R Kuritzkes; Catherine N Le; Jeffrey L Lennox; Kathryn I Pollak; Brian J Zikmund-Fisher; Karen A Scherr
Journal:  AIDS Behav       Date:  2020-07

Review 7.  The future of clinical trials in urological oncology.

Authors:  Vikram M Narayan; Philipp Dahm
Journal:  Nat Rev Urol       Date:  2019-10-11       Impact factor: 14.432

Review 8.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

9.  Overinterpretation and misreporting of prognostic factor studies in oncology: a systematic review.

Authors:  Emmanuelle Kempf; Jennifer A de Beyer; Jonathan Cook; Jane Holmes; Seid Mohammed; Tri-Long Nguyên; Iveta Simera; Marialena Trivella; Douglas G Altman; Sally Hopewell; Karel G M Moons; Raphael Porcher; Johannes B Reitsma; Willi Sauerbrei; Gary S Collins
Journal:  Br J Cancer       Date:  2018-10-24       Impact factor: 7.640

10.  Associations Between Characteristics of Web-Based Diabetes News and Readers' Sentiments: Observational Study in the Netherlands.

Authors:  Hans Vehof; Eibert Heerdink; José Sanders; Enny Das
Journal:  J Med Internet Res       Date:  2019-11-13       Impact factor: 5.428
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.